Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Great Novel Therapeutics Biotech & Medicals's Days Inventory for the
six
months ended in Dec. 2025 was 436.11.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Great Novel Therapeutics Biotech & Medicals's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.42.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Great Novel Therapeutics Biotech & Medicals's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 8.80.
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Great Novel Therapeutics Biotech & Medicals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Great Novel Therapeutics Biotech & Medicals's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Great Novel Therapeutics Biotech & Medicals Total Inventories Related Terms
Great Novel Therapeutics Biotech & Medicals Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Great Novel Therapeutics Biotech & Medicals Total Inventories Chart
Great Novel Therapeutics Biotech & Medicals Annual Data
Great Novel Therapeutics Biotech & Medicals Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of NT$7.30 Mil mean?
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a Total Inventories of NT$7.30 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Great Novel Therapeutics Biotech & Medicals and its competitors.
Is Great Novel Therapeutics Biotech & Medicals' Total Inventories too high?
Great Novel Therapeutics Biotech & Medicals' current Total Inventories is NT$7.30 Mil. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' Total Inventories compare to VRTX and REGN?
Great Novel Therapeutics Biotech & Medicals' Total Inventories of NT$7.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Great Novel Therapeutics Biotech & Medicals and its competitors. Great Novel Therapeutics Biotech & Medicals's current Total Inventories is NT$7.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.57, compared to a current price of NT$39.65 — trading 55.1% above its estimated fair value. The current Total Inventories is NT$7.30 Mil. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current Total Inventories is NT$7.30 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued.
The current stock price of NT$39.65 is trading 55.1% above its estimated GF Value™ of NT$25.57.
GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.
Key valuation signals for ROCO:7427:
Total Inventories: NT$7.30 Mil
GF Value™: NT$25.57 vs. price of NT$39.65 (55.1% above fair value)
No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Great Novel Therapeutics Biotech & Medicals Business Description
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
49GF Score
Get the complete analysis for ROCO:7427
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7427 has been successfully added to your 
